Home > Insider Trading > Filing (0000950170-24-097041)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1929561	Rxo Inc.	RXO	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1575023	Farhad Nanji	222 Berkeley Street, 13Th Floor Boston MA 02116	No	No	No	No
1732811	Mfn Partners Management, Lp	222 Berkeley Street, 13Th Floor Boston MA 02116	No	No	No	No
1732960	Mfn Partners, Lp	222 Berkeley Street, 13Th Floor Boston MA 02116	No	No	No	No
1814117	Michael Demichele	222 Berkeley Street, 13Th Floor Boston MA 02116	No	No	No	No
1814126	Mfn Partners Gp, Llc	222 Berkeley Street, 13Th Floor Boston MA 02116	No	No	No	No
1814127	Mfn Partners Management, Llc	222 Berkeley Street, 13Th Floor Boston MA 02116	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-08-12	10,266,810	$20.21	27,577,666	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrant to Purchase Common Stock	Acquisiton	2024-08-12	2,558,753	$20.20	2,558,753	$0.01

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,558,753			No	4	P	Direct

Footnotes

MFN Partners, LP (the "Partnership") is the holder of the securities reported herein. MFN Partners GP, LLC ("MFN GP") is the general partner of the Partnership. MFN Partners Management, LP ("MFN Management") is the investment adviser to the Partnership. MFN Partners Management, LLC ("MFN LLC") is the general partner of MFN Management. Farhad Nanji and Michael F. DeMichele are managing members of MFN GP and MFN LLC. Each Reporting Person disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest, if any, therein.
This Warrant can only be exercised to the extent that following such exercise the Partnership's beneficial ownership of the Issuer, together with any attribution parties, does not exceed 19.9%. The Warrant has no expiration date. This does not include an additional warrant for 2,018,574 shares of Common Stock with an exercise price of $0.01 and no expiration date, which becomes exercisable immediately upon the stockholders of the Issuer approving the issuance of the shares underlying that warrant pursuant to the applicable rules and regulations of the New York Stock Exchange. Upon such approval, that warrant can only be exercised to the extent that following such exercise the Partnership's beneficial ownership of the Issuer, together with any attribution parties, does not exceed 19.9%.